We have set up this channel to give you convenient access to the latest research in the area of Cancer-associated thrombosis (CAT) by providing a customised feed of abstracts of clinical papers published on PubMed. The combination of search terms providing the feed below is 'cancer AND thrombosis'. This channel is sorted chronologically. To see more information about a given paper, click the ‘Preview Abstract’ button below, and this will reveal an expanded abstract.
Eculizumab is first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH); however, approximately 11%-27% of patients may experience breakthrough hemolysis (BTH) on approved doses of eculizumab. Ravulizumab, a new long-acting C5 inhibitor with a four-times longer mean half-life than eculizumab, provides immediate, complete, and sustained C5 inhibition over 8-week dosing intervals. In two phase 3 studies, ravulizumab was noninferior to eculizumab (Pinf ≤0.0004) for the...
Exploiting the specific biological behaviors of the metabolizable nano-drugs assisted by X-rays exposure will be benefit for the optimization of radiotherapy-based combination therapy. Herein, Human serum albumin (HSA) nanoparticle, a familiar and metabolizable nanomaterial, is selected to investigate the changes of tumor accumulation and retention under X-rays exposure. Caveolin-1, an important protein which has positive correlation with cell uptake of nanomaterials, is...
BACKGROUND: Venous thromboembolism (VTE) is a significant source of postoperative morbidity and mortality in patients undergoing common oncologic procedures. We sought to estimate the effect of surgical approach on the risk of developing a VTE.
METHODS: IBM Watson Health Marketscan Database was used to conduct this retrospective study. In total, 12 938 patients who underwent either a radical prostatectomy, partial colectomy, or hysterectomy via a minimally invasive...
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is the third most common cause of vascular death after heart attack and stroke. Anticoagulation therapy is the cornerstone of VTE treatment. Despite such therapy, up to 50% of DVT patients develop post-thrombotic syndrome and up to 4% of PE patients develop chronic thromboembolic pulmonary hypertension. Therefore, better therapies are needed. Although the direct oral...
BACKGROUND: The commonest type of ischemic cerebral stroke in patients with cancer is cryptogenic stroke (CRS), the majority of which are considered cancer-associated strokes (CAS) caused by multiple microemboli associated with hypercoagulation, known as Trousseau syndrome. However, detection of microemboli and diagnosing CAS is difficult. We have therefore developed a scoring system for diagnosing CAS.
METHODS: We retrospectively examined data of patients with...
PURPOSE: Patients with hepatocellular carcinoma and portal vein tumor thrombus have a poor prognosis and limited therapeutic options. We sought to compare survival, tolerability, and safety in such patients treated with conventional yttrium-90 transarterial radioembolization dosimetric techniques or ablative transarterial radioembolization.
MATERIALS AND METHODS: This retrospective, single-center cohort study included patients with hepatocellular carcinoma and right,...
BACKGROUND: For locally advanced head and neck cancers, intra-arterial (IA) chemotherapy is utilized for locoregional control with favorable results. The study aimed to evaluate the surgical outcomes of microsurgical reconstruction in head and neck cancer patients with IA chemotherapy METHODS: This cohort study retrospectively reviewed patients who underwent head and neck microsurgical reconstruction from January 2014 to August 2018. Patients with prior history of...
Phosphoinositide 3-kinases (PI3Ks) are a family of ubiquitously distributed lipid kinases that control a wide variety of intracellular signaling pathways. Over the years, PI3K has emerged as an attractive target for the development of novel pharmaceuticals to treat cancer and various other diseases. In the last five years, four of the PI3K inhibitors viz. Idelalisib, Copanlisib, Duvelisib, and Alpelisib were approved by the FDA for the treatment of different types of cancer...
BACKGROUND: There are no tests to identify critically ill children at high risk of deep venous thrombosis (DVT). In this exploratory study, we aimed to identify proteins that are associated with incident DVT in critically ill adolescents.
PROCEDURE: Plasma samples were obtained from critically ill adolescents within 24 hours after initiation of cardiopulmonary support. The adolescents were followed with ultrasound to detect the development of DVT of the lower...
Introduction: The number of women and girls (WG) with bleeding disorders cared for at hemophilia treatment centers has increased dramatically over the last 30 years, owing to improved recognition of bleeding symptoms specific to WG. However, basic epidemiologic data of this population remain elusive. The ATHNdataset (American Thrombosis and Hemostasis Network) is a surveillance tool for people with bleeding disorders in the United States, providing demographic as well as...
ICTHIC Lunchtime Symposium April 2018: Dr Marc Carrier
ICTHIC Lunchtime Symposium April 2018: Alexander Cohen
ICTHIC Lunchtime Symposium April 2018: Dr Florian Langer MD
ICTHIC Lunchtime Symposium April 2018: Dr Luis Jara-Palomares, MN, PhD
Structured Modules in CAT
Nov 21, 2016
Oct 28, 2016
Oct 27, 2016
Sep 29, 2016
Please fill out the following form with your login credentials:
This website is intended to provide non-promotional, educational information to an international healthcare professional audience only.
You have indicated that you are not a healthcare professional and therefore, do not have access to this site.Please click here to continue browsing
This website is owned by LEO Pharma.
Cookies by themselves cannot be used to discover the identity of the user, and they do not in any way damage your computer.
We use a Google Analytics cookie, further information can be seen here:: Google Analytics Cookie Usage
The browsers of most computers, smartphones and other web-enabled devices are typically set up to accept cookies. If you wish to amend your cookie preferences for this site or any other websites, you can do this through your browser settings. Your browser's 'help' function will tell you how to do this.
However, please remember that cookies are often used to enable and improve certain functions on our site. If you therefore choose to disable the cookies that we use, this may impact your experience while on www.cathrombosis.com, for example, you may not be able to visit certain areas of the site and you may not receive personalised information.
If you use different devices to view and access the site (e.g. your computer, smartphone, tablet etc.) you will need to ensure that each browser on each device is adjusted to suit your cookie preferences.
For more information on how to disable cookies, visit www.allaboutcookies.org